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Acute diarrhoeal diseases, a major public-health 
problem in developing countries, are often associa-
ted with significant morbidity and mortality, es-
pecially among children (1-4). Of the pathogens 
causing diarrhoea, Shigella continues to play a 
major role in aetiology of inflammatory diarrhoea 
and dysentery, thus presenting a serious challenge 
to public-health authorities worldwide (5-7). A re-
cent epidemiological report by Niyogi in 2005 (8) 
concluded that annually an estimated 165 million 
children and young adults worldwide suffer from 
shigellosis and that 99% occur in developing coun-
tries, and in developing countries, 69% of cases oc-
cur in children aged less then five years (9). These 
organisms belong to the Enterobacteriaceae family, 
with four serogroups described: Shigella dysenteriae, 
S. flexneri, S. sonnei, and S. boydii. S. dysenteriae, first 
described by Kiyoshi Shiga in 1897 (10), was a ma-
jor cause of mortality during World War I, but de-
creased in prevalence after the war and was rapidly 
replaced by S. flexneri as the major serogroup, which 
caused a broader spectrum of diarrhoeal illnesses 
ranging from mild to very severe (6). After World 
War II, S. sonnei replaced S. flexneri as the dominant 
pathogen in most developed and some develop-
ing countries (6,11-13). Shigella species have been 
found in most surface-waters, sewage, food, and 
crops contaminated by human faeces used as fertili-
zer (14,15). Although recovered from these sources, 
Shigella species are most frequently transmitted via 
direct person-to-person contact, and 10-100 organ-
isms are required to start an infection (16).
In the late 1960s, S. dysenteriae type 1 was respon-
sible for an epidemic in Guatemala, resulting in 
significant morbidity and mortality in that South 
American country (17). Subsequent to this out-
break, S. dysenteriae appeared in Asia and Africa and 
is now endemic in these regions (18-20). 
Effective antimicrobial treatment for shigellosis has 
been shown to reduce its duration and severity, re-
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duce shedding of the organisms and prevent po-
tentially lethal complications (4). However, due to 
the global emergence of drug-resistance, the choice 
of antimicrobial agents for treating shigellosis is 
limited (21). Over the past 15 years, Shigellae have 
become progressively resistant to most widely-
used and inexpensive antimicrobials, and changes 
in the incidence of these organisms from time to 
time have resulted in some challenges in formulat-
ing a drug of choice for therapeutic management 
of shigellosis. In Taiwan, 128 strains of Shigella 
tested against 11 antimicrobials were resistant to 
ampicillin (52%), chloramphenicol (84%), strepto-
mycin (84%), and tetracycline (88%) (22). Reports 
from Indonesia (6), Bangladesh (23), Malaysia (5), 
and Nepal (24) showed increasing frequency of 
Shigella with multiple resistance to ampicillin, tri-
methoprim-sulphamethoxazole, tetracycline, and 
nalidixic acid. Similar resistance profiles were re-
ported from Africa (19), Central America (17), Eu-
rope (25-27), and South America (28-29). Although 
antimicrobial resistance among Shigella species is 
well-documented in many countries, there is a lack 
of such documentation in Trinidad. The study was, 
therefore, undertaken to determine the frequency 
and serogroup distribution of Shigella from stools 
of patients with acute diarrhoea and to understand 
their resistant profiles to commonly-used antimi-
crobials, thus allowing for more appropriate man-
agement of shigellosis. 
MATERIALS AND METHODS
Study area and population
During 1 January 1997–31 December 2006, stool 
specimens from outpatients who presented at the 
Accident and Emergency Department of the San 
Fernando General Hospital (SFGH), health centres, 
outpatient clinics at the SFGH, and offices of general 
practitioners with acute diarrhoea were received in 
the microbiology laboratory of the SFGH for analy-
sis according to the standard methods (30). These 
patients came from both rural and urban areas. It 
was not possible to definitely assign any patient 
solely to either urban or rural areas because patients 
have relatives from both the areas and have used 
their addresses interchangeably. The SFGH is a 650-
bed tertiary hospital located in the southern part of 
Trinidad. Trinidad is the larger island of the twin-
island Republic—Trinidad and Tobago—located 
about 11 km off the northern coast of Venezuela in 
South America. The population of the Republic is 
about 1.3 million, and the SFGH serves a popula-
tion of about 400,000. Specimens were transported 
in wide-mouth screw-on-top sterile containers and 
were processed within two hours of arrival in the 
laboratory. 
Bacteriological analysis
Stool specimens were primarily inoculated directly 
onto MacConkey agar and xylose-lysine deoxycho-
late (XLD) agar. All plates were incubated aerobi-
cally at 35-37 0C for 18-24 hours. Lactose-non-fer-
menting colonies, morphologically resembling 
Shigella, were picked and again subcultured onto 
MacConkey and XLD media and were further iden-
tified biochemically using urea, triple sugar iron, 
sulphide-indole motility medium, and Simmons 
citrate media. Biochemically-screened strains of 
Shigella were further identified serologically to spe-
cies level using polyvalent and monovalent anti-
sera by the Caribbean Epidemiological Center 
(CAREC). CAREC, the regional branch of Pan 
American Health Organization/World Health Or-
ganization, is the reference laboratory for 19 Carib-
bean countries, including Trinidad and Tobago.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed 
by the disc-diffusion method using the guidelines 
and interpretative criteria of the Clinical Laborato-
ry Standards Institute (CLSI) (30), with the follow-
ing antimicrobials and concentrations: ampicillin 
(10 μg), tetracycline (30 µg), trimethoprim-sulpha-
methoxazole (1.25/23.75 µg), amoxicillin-clavu-
lanic acid (20/10 µg), cefuroxime (30 µg), chloram-
phenicol (30 µg), ciprofloxacin (5 µg), aztreonam 
(30 µg), and gentamicin (10 µg) (Oxoid, UK).  Mul-
tidrug resistance was defined as resistance to three 
or more antimicrobials. The control organism was 
Escherichia coli ATCC 25922 strain obtained from 
the CAREC.
Statistical analysis was performed using the SPSS 
software (version 12) (SPSS Inc., Chicago, Ill, USA), 
where prevalence was compared using chi-square.
RESULTS
During the study period, 392 Shigella organisms 
were recovered from 5,187 stool specimens. The 
yearly distribution of these organisms is shown in 
Table 1. The number of stool specimens submit-
ted each year to the laboratory remained relatively 
stable over the 10-year period. The predominant 
serogroup was S. sonnei which accounted for 75% 
(294/392) of all isolates, followed by S. flexneri (19%; 
75/392), S. boydii, (4.1%; 16/392), and S. dysenteriae 
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from 44 (11.0%) isolates in 1997 to 26 (4.3%) iso-
lates in 2006, and this was statistically significant 
(p<0.001). A similar pattern was observed for S. 
flexneri which decreased from 17 (4.3 %) in 1997 to 
5 (0.8%) in 2006 (p<0.001). The isolation rates of S. 
boydii and S. dysenteriae remained relatively stable 
during the entire period. 
Table 2 shows the distribution of Shigella according 
to age-group. Shigella was isolated most frequent-
ly from the >0-10 years age-group. Almost 89% 
(348/392) of the isolates were recovered from stool 
specimens of this age-group, and the predomi-
nant serogroup was S. sonnei which accounted for 
81% (n=280) of the 348 isolates. Also, among this 
age-group, S. flexneri was the next major serogroup 
isolated, accounting for 65% of all S. flexneri strains 
in this study. Among the >20-30 years age-group, S. 
flexneri was the most frequent serogroup recovered 
from diarrhoeal stool. The other serogroups—S. 
boydii and S. dysenteriae—were infrequently recov-
ered from patients. Overall, S. sonnei and S. flexneri 
were responsible for 94% (369/392) of all the cases 
of shigellosis, and the former is the predominant 
serogroup in Trinidad.
The resistance rates of Shigella serogroups dur-
ing the study period are shown in Table 3. Of the 
392 Shigella isolates which included the four sero-
groups, only S. sonnei serogroup showed resistance 
to all nine antimicrobials. Among all serogroups, 
the most common resistance was to ampicillin. S. 
boydii and S. sonnei were more frequently resistant 
to tetracycline (37% and 36% respectively) than 
the other serogroups. All S. flexneri, S. boydii and S. 
dysenteriae serogroups were fully sensitive to aztreo-
Table 1. Yearly distribution and infection of Shigella serogroups from stool specimens of patients with 
diarrhoea at San Fernando General Hospital, 1997-2006
Year


















1997 399 44 (11) 17 (4.3) 2 (0.5) 0 63 (16)
1998 570 52 (9) 9 (1.6) 3 (0.5) 1 (0.2) 65 (11)
1999 713 43 (6) 13 (1.8) 3 (0.4) 0 59 (8)
2000 498 18 (3.6) 5 (1.0) 2 (0.4) 1 (0.2) 26 (5)
2001 489 15 (3.1) 8 (1.6) 1 (0.2) 0 24 (4.9)
2002 427 23 (5) 6 (1.4) 0 1 (0.2) 30 (7)
2003 467 17 (3.6) 6 (1.3) 1 (0.2) 1 (0.2) 25 (5)
2004 533 23 (4.3) 5 (0.9) 1 (0.2) 1 (0.2) 30 (6)
2005 487 33 (7) 1 (0.2) 1 (0.2) 0 35 (7)
2006 604 26 (4.3) 5 (0.8) 2 (0.3) 2 (0.3) 35 (6)
Total 5,187 294 (6) 75 (1.4) 16 (0.3) 7 (0.1) 392 (8)
There were significant falls in isolation (p<0.001) for both S. sonnei (44 to 26) and S. flexneri (17 to 5) for 
1997 vs 2006






















0-10 4,876 280 (15) 49 (1.0) 13 (0.3) 6 (0.1) 348 (16)
>10-20 74 7 (12) 6 (6) 1 (1.1) 0 14 (19)
>20-30 60 2 (3.3) 16 (27) 0 1 (1.7) 19 (32)
>30-40 39 2 (5) 1 (2.6) 0 0 3 (8)
>40-50 39 1 (2.6) 0 0 0 1 (2.6)
>50 99 2 (2.0) 3 (3.0) 2 (2.0) 0 7 (7.0)
Total 5,187 294 (15) 75 (1.4) 16 (0.3) 7 (0.1) 392 (8)Orrett FA Antimicrobial resistance of Shigella
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nam, gentamicin, and ciprofloxacin. Although 
varying degrees of resistance were noted to most 
drugs, susceptibility ranged from 52% to 100% for 
the most common serogroups recovered.  
DISCUSSION
Shigella was recovered from 8% of cases of acute 
infectious diarrhoea during the study period. This 
rate is comparable with studies from Israel (31), In-
donesia  (6), Nepal (32), and Ghana (33) that docu-
mented rates of 3.3%, 3.8%, 4.0%, and 5% respec-
tively, but differed from higher rates reported from 
Bangladesh (58%) (23), Uganda (35%) (34), and 
Ethiopia (20%) (35). The low rate of isolation as 
observed in the present study maybe due, in part, 
to continuing educational programmes at elemen-
tary schools, aggressive infection-control measures 
in our hospital and healthcare centres, and possi-
bly under-reporting of shigellosis cases by general 
practitioners. Shigellosis is primarily a childhood 
disease in both developed and developing coun-
tries whereas epidemic of shigellosis affects all age-
groups (36). In this study, shigellosis was observed 
in all age-groups but was the highest among the 
>0-10 years age-group. Children within this age-
group are most susceptible to shigellosis primarily 
because of poor resistance, lack of previous expo-
sure, poor personal hygiene, and higher exposure 
to contaminated environment due to play-related 
activities (18,37).
All four serogroups of Shigella co-exist in different 
proportions in many countries. However, in most 
developing countries, S. flexneri is the predomi-
nant Shigella serogroup isolated from patients with 
infectious diarrhoea and represents 50-90% of all 
Shigella isolates (5,24,36,37). Our findings are in 
sharp contrast to these reports and agree with oth-
ers from several developing countries where the 
predominant serogroup is S. sonnei, followed by S. 
flexneri (11,38-40). The other serogroups—S. boydii 
and S. dysenteriae—were infrequently isolated. The 
predominance of S sonnei did not change since the 
last decade as was evident in two previous reports 
from this country (7,41). This predominance was 
unlike the situation in the islands of Bengal (42) 
where S. flexneri and S. dysenteriae alternated as the 
most active agents of shigellosis.
Antimicrobial therapy is the cornerstone of treat-
ment of shigellosis. The guiding principle for the 
choice of antimicrobial in developing countries 
includes the cost, availability of the drug, and the 
patterns of resistance in the community (21). The 
prevalence of resistance for the most prevalent se-
rogroup—S. sonnei—during the study period ranged 
from 0.7% for ciprofloxacin to 36% for tetracycline. 
The prevalence of resistance was 1.4% for augmen-
tin, cefuroxime, chloramphenicol, aztreonam, and 
gentamicin. Gram-negative bacterial resistance to 
tetracycline has always been variable and ranged 
from 6% to 78% (7,43-45). Antimicrobials are recom- 
mended for shigellosis because antimicrobials 
shorten the severity and duration of illness, reduce 
shedding of the organisms, and prevent subse-
quent infection by family contacts, development 
of secondary complications, and death. Antimicro-
bial resistance among Shigella has occurred since 
the 1940s when sulphonamide resistance among 
Shigella was first recognized in Japan (46). Since 
then, resistance to sulphonamide and other drugs 
has been increasing worldwide due to the excessive 













Tetracycline 36 12.0 38 0 32
Co-trimoxazole* 33 21 19 0 30
Ampicillin 9 48 63 100 16
Augmentin† 1.4 9 19 57 3.0
Cefuroxime 1.4 9 19 57 3.0
Chloramphenicol 1.4 0 19 0 1.5
Aztreonam 1.4 0 0 0 1.0
Gentamicin 1.4 0 0 0 1.0
Ciprofloxacin 0.7 0 0 0 0.5
*Trimethoprim-sulphamethoxazole; †Amoxicillin-clavulanic acidOrrett FA Antimicrobial resistance of Shigella
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use of antimicrobial agents and failure to prevent 
the spread of multidrug-resistant strains of Shigella. 
This changing pattern of antimicrobial susceptibili-
ty among Shigella serogroups poses a major prob-
lem in the determination of an appropriate drug 
for the treatment of Shigella-associated infections. 
S. sonnei was significantly more resistant to com-
mon antimicrobial agents, mainly tetracycline and 
co-trimoxazole, than were the other Shigella sero-
groups. These data need to be emphasized because 
S. sonnei is the predominant serogroup not only in 
this country but in the USA and other developed 
countries as well. The highest resistance to ampicil-
lin was noted among the other Shigella serogroups 
(48-100%). While this is important to note, these 
isolates comprise less than 6% of the total Shigella 
serogroups recovered from stools. Aztreonam, gen-
tamicin and the fluoroquinolone, ciprofloxacin, 
are the three drugs that show the greatest efficacy 
against all serogroups of Shigella in this study. Most 
cases of shigellosis occur in children aged less than 
10 years. Of these three drugs, only ciprofloxacin 
is available for oral therapy, but paediatric use is 
limited by concerns about arthopathy and chron-
drotoxicity. However, reports suggest that the fluo-
roquinolones are generally safe for the treatment of 
shigellosis in children (47,48). 
The present study demonstrated that S. sonnei re-
mained the predominant serogroup in Trinidad for 
the past 10 years. The data also showed that, al-
though resistant strains exist among all serogroups, 
this resistance was relatively low and that most 
drugs are still efficacious in the empirical treatment 
of shigellosis, particularly ciprofloxacin, aztreonam, 
gentamicin, chloramphenicol, and trimethoprim-
sulphamethoxazole. These findings confirm the 
need to formulate long-term surveillance pro-
grammes that would identify changes in antimicro-
bial susceptibility patterns and the dissemination of 
such information to clinicians.
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